Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes
Background Atherosclerosis is an inflammatory disease. Monocyte chemoattractant protein‐1 (MCP‐1) is an essential chemokine responsible for the recruitment of monocytes to inflammatory lesions in the vasculature, an initial step of atherosclerosis. Since serum levels of MCP‐1 are higher in patients...
Gespeichert in:
| Veröffentlicht in: | Diabetes/metabolism research and reviews 2008-02, Vol.24 (2), p.109-114 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 114 |
|---|---|
| container_issue | 2 |
| container_start_page | 109 |
| container_title | Diabetes/metabolism research and reviews |
| container_volume | 24 |
| creator | Nakamura, Kazuo Yamagishi, Sho-ichi Adachi, Hisashi Matsui, Takanori Kurita-Nakamura, Yayoi Takeuchi, Masayoshi Inoue, Hiroyoshi Imaizumi, Tsutomu |
| description | Background
Atherosclerosis is an inflammatory disease. Monocyte chemoattractant protein‐1 (MCP‐1) is an essential chemokine responsible for the recruitment of monocytes to inflammatory lesions in the vasculature, an initial step of atherosclerosis. Since serum levels of MCP‐1 are higher in patients with type 2 diabetes, inhibition of MCP‐1 may be a novel therapeutic target for prevention of accelerated atherosclerosis in diabetes. However, little is known about the regulation and determinants of serum MCP‐1 levels in patients with diabetes. In this study, we examined the determinants of serum MCP‐1 levels in type 2 diabetic patients.
Methods
Eighty‐six consecutive outpatients with type 2 diabetes (36 male and 50 female; mean age 68.4 ± 9.6) underwent a complete history and physical examination, determination of blood chemistries, MCP‐1, tumour necrosis factor‐α, adiponectin, advanced glycation end products (AGEs), and soluble form of receptor for AGEs (sRAGE). We examined the association between MCP‐1 levels and those in anthropometric, metabolic and inflammatory variables in these subjects.
Results
Univariate regression analysis showed that serum levels of MCP‐1 were positively associated with AGEs (r = 0.386, p < 0.001) and sRAGE (r = 0.315, p < 0.001). After adjusting for age and sex, AGEs (p < 0.001) and sRAGE (p < 0.05) still remained significant.
Conclusion
The results demonstrate for the first time that circulating levels of AGEs and sRAGE are independent determinants of serum MCP‐1 levels in patients with type 2 diabetes. Our present observations suggest the AGEs‐RAGE system may be mainly involved in the elevation of MCP‐1 in type 2 diabetic patients. Copyright © 2007 John Wiley & Sons, Ltd. |
| doi_str_mv | 10.1002/dmrr.766 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70262921</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21109840</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4226-6287a0d119a54dff2e687f0924a7fd410b736efb9a57bc6239118a30f8a4d27d3</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhiMEoqUg8QTIJ7Q9pNhOYm-OJbQLUhfQqrBHy7EnrSGxg-203UflbXC0q3JCnMaa-fzNSH-WvSb4jGBM3-nB-zPO2JPsmFQU57xi-Onju6JH2YsQfmCMi5KVz7MjwlldVrg8zn43xqupl9HYGyT1nbQKNLrpdyq1nEVgNRq905OKAS3OVxfhFMnUC66f2h5Q5_yAXIc8KBij83MDzRhahE2qifaAjNUwJhXYiDRE8IOx0iZj-hnATwManHVqFwGpWxicjNFLFRMyL49gbE7QYt18zckp6uEO-pCcaEw3wqy5N_EWxd0IiCJtZJtWhJfZs072AV4d6kn27fLiuvmYX31ZfWrOr3JVUspyRpdcYk1ILatSdx0FtuQdrmkpeadLglteMOjaNOatYrSoCVnKAndLWWrKdXGSvd1706W_JghRDCYo6HtpwU1BcEwZrSn5L0gJwfWyxAlc7EHlXQgeOjF6M0i_EwSLOW8x5y1S3gl9c3BO7QD6L3gIOAH5Hrg3Pez-KRIf1pvNXnjgTYjw8MhL_1MwXvBKbD-vxPf3TbPl62uxLf4AYHPGiA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21109840</pqid></control><display><type>article</type><title>Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Nakamura, Kazuo ; Yamagishi, Sho-ichi ; Adachi, Hisashi ; Matsui, Takanori ; Kurita-Nakamura, Yayoi ; Takeuchi, Masayoshi ; Inoue, Hiroyoshi ; Imaizumi, Tsutomu</creator><creatorcontrib>Nakamura, Kazuo ; Yamagishi, Sho-ichi ; Adachi, Hisashi ; Matsui, Takanori ; Kurita-Nakamura, Yayoi ; Takeuchi, Masayoshi ; Inoue, Hiroyoshi ; Imaizumi, Tsutomu</creatorcontrib><description>Background
Atherosclerosis is an inflammatory disease. Monocyte chemoattractant protein‐1 (MCP‐1) is an essential chemokine responsible for the recruitment of monocytes to inflammatory lesions in the vasculature, an initial step of atherosclerosis. Since serum levels of MCP‐1 are higher in patients with type 2 diabetes, inhibition of MCP‐1 may be a novel therapeutic target for prevention of accelerated atherosclerosis in diabetes. However, little is known about the regulation and determinants of serum MCP‐1 levels in patients with diabetes. In this study, we examined the determinants of serum MCP‐1 levels in type 2 diabetic patients.
Methods
Eighty‐six consecutive outpatients with type 2 diabetes (36 male and 50 female; mean age 68.4 ± 9.6) underwent a complete history and physical examination, determination of blood chemistries, MCP‐1, tumour necrosis factor‐α, adiponectin, advanced glycation end products (AGEs), and soluble form of receptor for AGEs (sRAGE). We examined the association between MCP‐1 levels and those in anthropometric, metabolic and inflammatory variables in these subjects.
Results
Univariate regression analysis showed that serum levels of MCP‐1 were positively associated with AGEs (r = 0.386, p < 0.001) and sRAGE (r = 0.315, p < 0.001). After adjusting for age and sex, AGEs (p < 0.001) and sRAGE (p < 0.05) still remained significant.
Conclusion
The results demonstrate for the first time that circulating levels of AGEs and sRAGE are independent determinants of serum MCP‐1 levels in patients with type 2 diabetes. Our present observations suggest the AGEs‐RAGE system may be mainly involved in the elevation of MCP‐1 in type 2 diabetic patients. Copyright © 2007 John Wiley & Sons, Ltd.</description><identifier>ISSN: 1520-7552</identifier><identifier>EISSN: 1520-7560</identifier><identifier>DOI: 10.1002/dmrr.766</identifier><identifier>PMID: 17694504</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Aged ; AGEs ; atherosclerosis ; Chemokine CCL2 - blood ; diabetes ; Diabetes Mellitus, Type 2 - blood ; Female ; Glycation End Products, Advanced - blood ; Humans ; Male ; MCP-1 ; Middle Aged ; Receptor for Advanced Glycation End Products ; Receptors, Immunologic - blood ; Regression Analysis ; Solubility ; sRAGE</subject><ispartof>Diabetes/metabolism research and reviews, 2008-02, Vol.24 (2), p.109-114</ispartof><rights>Copyright © 2007 John Wiley & Sons, Ltd.</rights><rights>Copyright (c) 2007 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4226-6287a0d119a54dff2e687f0924a7fd410b736efb9a57bc6239118a30f8a4d27d3</citedby><cites>FETCH-LOGICAL-c4226-6287a0d119a54dff2e687f0924a7fd410b736efb9a57bc6239118a30f8a4d27d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fdmrr.766$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fdmrr.766$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17694504$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakamura, Kazuo</creatorcontrib><creatorcontrib>Yamagishi, Sho-ichi</creatorcontrib><creatorcontrib>Adachi, Hisashi</creatorcontrib><creatorcontrib>Matsui, Takanori</creatorcontrib><creatorcontrib>Kurita-Nakamura, Yayoi</creatorcontrib><creatorcontrib>Takeuchi, Masayoshi</creatorcontrib><creatorcontrib>Inoue, Hiroyoshi</creatorcontrib><creatorcontrib>Imaizumi, Tsutomu</creatorcontrib><title>Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes</title><title>Diabetes/metabolism research and reviews</title><addtitle>Diabetes Metab. Res. Rev</addtitle><description>Background
Atherosclerosis is an inflammatory disease. Monocyte chemoattractant protein‐1 (MCP‐1) is an essential chemokine responsible for the recruitment of monocytes to inflammatory lesions in the vasculature, an initial step of atherosclerosis. Since serum levels of MCP‐1 are higher in patients with type 2 diabetes, inhibition of MCP‐1 may be a novel therapeutic target for prevention of accelerated atherosclerosis in diabetes. However, little is known about the regulation and determinants of serum MCP‐1 levels in patients with diabetes. In this study, we examined the determinants of serum MCP‐1 levels in type 2 diabetic patients.
Methods
Eighty‐six consecutive outpatients with type 2 diabetes (36 male and 50 female; mean age 68.4 ± 9.6) underwent a complete history and physical examination, determination of blood chemistries, MCP‐1, tumour necrosis factor‐α, adiponectin, advanced glycation end products (AGEs), and soluble form of receptor for AGEs (sRAGE). We examined the association between MCP‐1 levels and those in anthropometric, metabolic and inflammatory variables in these subjects.
Results
Univariate regression analysis showed that serum levels of MCP‐1 were positively associated with AGEs (r = 0.386, p < 0.001) and sRAGE (r = 0.315, p < 0.001). After adjusting for age and sex, AGEs (p < 0.001) and sRAGE (p < 0.05) still remained significant.
Conclusion
The results demonstrate for the first time that circulating levels of AGEs and sRAGE are independent determinants of serum MCP‐1 levels in patients with type 2 diabetes. Our present observations suggest the AGEs‐RAGE system may be mainly involved in the elevation of MCP‐1 in type 2 diabetic patients. Copyright © 2007 John Wiley & Sons, Ltd.</description><subject>Aged</subject><subject>AGEs</subject><subject>atherosclerosis</subject><subject>Chemokine CCL2 - blood</subject><subject>diabetes</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Female</subject><subject>Glycation End Products, Advanced - blood</subject><subject>Humans</subject><subject>Male</subject><subject>MCP-1</subject><subject>Middle Aged</subject><subject>Receptor for Advanced Glycation End Products</subject><subject>Receptors, Immunologic - blood</subject><subject>Regression Analysis</subject><subject>Solubility</subject><subject>sRAGE</subject><issn>1520-7552</issn><issn>1520-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1DAQhiMEoqUg8QTIJ7Q9pNhOYm-OJbQLUhfQqrBHy7EnrSGxg-203UflbXC0q3JCnMaa-fzNSH-WvSb4jGBM3-nB-zPO2JPsmFQU57xi-Onju6JH2YsQfmCMi5KVz7MjwlldVrg8zn43xqupl9HYGyT1nbQKNLrpdyq1nEVgNRq905OKAS3OVxfhFMnUC66f2h5Q5_yAXIc8KBij83MDzRhahE2qifaAjNUwJhXYiDRE8IOx0iZj-hnATwManHVqFwGpWxicjNFLFRMyL49gbE7QYt18zckp6uEO-pCcaEw3wqy5N_EWxd0IiCJtZJtWhJfZs072AV4d6kn27fLiuvmYX31ZfWrOr3JVUspyRpdcYk1ILatSdx0FtuQdrmkpeadLglteMOjaNOatYrSoCVnKAndLWWrKdXGSvd1706W_JghRDCYo6HtpwU1BcEwZrSn5L0gJwfWyxAlc7EHlXQgeOjF6M0i_EwSLOW8x5y1S3gl9c3BO7QD6L3gIOAH5Hrg3Pez-KRIf1pvNXnjgTYjw8MhL_1MwXvBKbD-vxPf3TbPl62uxLf4AYHPGiA</recordid><startdate>200802</startdate><enddate>200802</enddate><creator>Nakamura, Kazuo</creator><creator>Yamagishi, Sho-ichi</creator><creator>Adachi, Hisashi</creator><creator>Matsui, Takanori</creator><creator>Kurita-Nakamura, Yayoi</creator><creator>Takeuchi, Masayoshi</creator><creator>Inoue, Hiroyoshi</creator><creator>Imaizumi, Tsutomu</creator><general>John Wiley & Sons, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200802</creationdate><title>Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes</title><author>Nakamura, Kazuo ; Yamagishi, Sho-ichi ; Adachi, Hisashi ; Matsui, Takanori ; Kurita-Nakamura, Yayoi ; Takeuchi, Masayoshi ; Inoue, Hiroyoshi ; Imaizumi, Tsutomu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4226-6287a0d119a54dff2e687f0924a7fd410b736efb9a57bc6239118a30f8a4d27d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aged</topic><topic>AGEs</topic><topic>atherosclerosis</topic><topic>Chemokine CCL2 - blood</topic><topic>diabetes</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Female</topic><topic>Glycation End Products, Advanced - blood</topic><topic>Humans</topic><topic>Male</topic><topic>MCP-1</topic><topic>Middle Aged</topic><topic>Receptor for Advanced Glycation End Products</topic><topic>Receptors, Immunologic - blood</topic><topic>Regression Analysis</topic><topic>Solubility</topic><topic>sRAGE</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakamura, Kazuo</creatorcontrib><creatorcontrib>Yamagishi, Sho-ichi</creatorcontrib><creatorcontrib>Adachi, Hisashi</creatorcontrib><creatorcontrib>Matsui, Takanori</creatorcontrib><creatorcontrib>Kurita-Nakamura, Yayoi</creatorcontrib><creatorcontrib>Takeuchi, Masayoshi</creatorcontrib><creatorcontrib>Inoue, Hiroyoshi</creatorcontrib><creatorcontrib>Imaizumi, Tsutomu</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes/metabolism research and reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakamura, Kazuo</au><au>Yamagishi, Sho-ichi</au><au>Adachi, Hisashi</au><au>Matsui, Takanori</au><au>Kurita-Nakamura, Yayoi</au><au>Takeuchi, Masayoshi</au><au>Inoue, Hiroyoshi</au><au>Imaizumi, Tsutomu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes</atitle><jtitle>Diabetes/metabolism research and reviews</jtitle><addtitle>Diabetes Metab. Res. Rev</addtitle><date>2008-02</date><risdate>2008</risdate><volume>24</volume><issue>2</issue><spage>109</spage><epage>114</epage><pages>109-114</pages><issn>1520-7552</issn><eissn>1520-7560</eissn><abstract>Background
Atherosclerosis is an inflammatory disease. Monocyte chemoattractant protein‐1 (MCP‐1) is an essential chemokine responsible for the recruitment of monocytes to inflammatory lesions in the vasculature, an initial step of atherosclerosis. Since serum levels of MCP‐1 are higher in patients with type 2 diabetes, inhibition of MCP‐1 may be a novel therapeutic target for prevention of accelerated atherosclerosis in diabetes. However, little is known about the regulation and determinants of serum MCP‐1 levels in patients with diabetes. In this study, we examined the determinants of serum MCP‐1 levels in type 2 diabetic patients.
Methods
Eighty‐six consecutive outpatients with type 2 diabetes (36 male and 50 female; mean age 68.4 ± 9.6) underwent a complete history and physical examination, determination of blood chemistries, MCP‐1, tumour necrosis factor‐α, adiponectin, advanced glycation end products (AGEs), and soluble form of receptor for AGEs (sRAGE). We examined the association between MCP‐1 levels and those in anthropometric, metabolic and inflammatory variables in these subjects.
Results
Univariate regression analysis showed that serum levels of MCP‐1 were positively associated with AGEs (r = 0.386, p < 0.001) and sRAGE (r = 0.315, p < 0.001). After adjusting for age and sex, AGEs (p < 0.001) and sRAGE (p < 0.05) still remained significant.
Conclusion
The results demonstrate for the first time that circulating levels of AGEs and sRAGE are independent determinants of serum MCP‐1 levels in patients with type 2 diabetes. Our present observations suggest the AGEs‐RAGE system may be mainly involved in the elevation of MCP‐1 in type 2 diabetic patients. Copyright © 2007 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>17694504</pmid><doi>10.1002/dmrr.766</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1520-7552 |
| ispartof | Diabetes/metabolism research and reviews, 2008-02, Vol.24 (2), p.109-114 |
| issn | 1520-7552 1520-7560 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70262921 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged AGEs atherosclerosis Chemokine CCL2 - blood diabetes Diabetes Mellitus, Type 2 - blood Female Glycation End Products, Advanced - blood Humans Male MCP-1 Middle Aged Receptor for Advanced Glycation End Products Receptors, Immunologic - blood Regression Analysis Solubility sRAGE |
| title | Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T21%3A06%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20advanced%20glycation%20end%20products%20(AGEs)%20and%20soluble%20form%20of%20receptor%20for%20AGEs%20(sRAGE)%20are%20independent%20determinants%20of%20serum%20monocyte%20chemoattractant%20protein-1%20(MCP-1)%20levels%20in%20patients%20with%20type%202%20diabetes&rft.jtitle=Diabetes/metabolism%20research%20and%20reviews&rft.au=Nakamura,%20Kazuo&rft.date=2008-02&rft.volume=24&rft.issue=2&rft.spage=109&rft.epage=114&rft.pages=109-114&rft.issn=1520-7552&rft.eissn=1520-7560&rft_id=info:doi/10.1002/dmrr.766&rft_dat=%3Cproquest_cross%3E21109840%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21109840&rft_id=info:pmid/17694504&rfr_iscdi=true |